Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E18.68 EPS (ttm)5.65 Insider Own0.40% Shs Outstand1.51B Perf Week1.18%
Market Cap159.22B Forward P/E10.49 EPS next Y10.06 Insider Trans-5.18% Shs Float1.50B Perf Month1.76%
Income9.41B PEG0.75 EPS next Q2.23 Inst Own87.40% Short Float3.77% Perf Quarter-0.40%
Sales20.70B P/S7.69 EPS this Y10.40% Inst Trans-6.06% Short Ratio3.76 Perf Half Y29.98%
Book/sh8.96 P/B11.78 EPS next Y26.96% ROA34.00% Target Price126.17 Perf Year43.42%
Cash/sh4.19 P/C25.21 EPS next 5Y24.76% ROE69.10% 52W Range63.50 - 116.83 Perf YTD40.53%
Dividend- P/FCF15.82 EPS past 5Y11.90% ROI18.70% 52W High-9.66% Beta0.70
Dividend %- Quick Ratio1.80 Sales past 5Y16.00% Gross Margin82.70% 52W Low66.20% ATR2.90
Employees6100 Current Ratio2.10 Sales Q/Q117.10% Oper. Margin58.60% RSI (14)55.43 Volatility2.83% 2.62%
OptionableYes Debt/Eq0.69 EPS Q/Q255.30% Profit Margin45.40% Rel Volume0.95 Prev Close102.40
ShortableYes LT Debt/Eq0.58 EarningsOct 28 AMC Payout0.00% Avg Volume15.03M Price105.54
Recom1.70 SMA203.13% SMA501.00% SMA20015.47% Volume14,233,530 Change3.07%
Dec-09-14Reiterated Argus Buy $110 → $130
Oct-29-14Reiterated RBC Capital Mkts Outperform $115 → $125
Oct-13-14Reiterated FBR Capital Outperform $125 → $130
Sep-25-14Reiterated Needham Buy $95 → $120
Aug-22-14Reiterated RBC Capital Mkts Outperform $102 → $115
Aug-15-14Initiated FBR Capital Outperform $125
Aug-11-14Reiterated Argus Buy $90 → $110
Jul-28-14Reiterated Maxim Group Buy $112 → $127
Jul-24-14Reiterated RBC Capital Mkts Outperform $96 → $102
Apr-28-14Reiterated Maxim Group Buy $101 → $112
Feb-21-14Reiterated Barclays Overweight $90 → $95
Feb-10-14Reiterated Argus Buy $84 → $90
Feb-05-14Reiterated RBC Capital Mkts Outperform $90 → $96
Feb-05-14Reiterated Needham Buy $85 → $95
Feb-05-14Reiterated Maxim Group Buy $98 → $101
Feb-04-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
Jan-28-14Reiterated Deutsche Bank Buy $95 → $132
Jan-06-14Reiterated UBS Buy $80 → $102
Jan-02-14Reiterated Maxim Group Buy $89 → $98
Dec-20-13Reiterated RBC Capital Mkts Outperform $80 → $90
Dec-18-14 01:05PM  CVS' Plan to Foment a Hep C Pricing War Between Gilead, Abbvie Yahoo Finance Blogs
11:14AM  Biotech: More Upside in 2015? at Barrons.com
09:35AM  2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses at TheStreet
Dec-16-14 09:03PM  Meet 5 Big Tech Stocks Expected To See Profits Surge at Investor's Business Daily
10:21AM  Viekirax/Exviera vs. Harvoni: Clash of the Hep C Drugs 2015 Yahoo Finance Blogs
Dec-15-14 04:44PM  Where is Santa rally? Yahoo Finance Blogs
12:56PM  Gilead Sciences: What Its New Hire Means for Its Cancer Pipeline at Barrons.com
08:30AM  Philippe C. Bishop, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutics Business Wire
Dec-13-14 08:02AM  Meet 5 Top Biotech Stocks Holding Up In Shaky Market at Investor's Business Daily
Dec-12-14 11:44AM  These 2 Biotech Stocks Are Set To Split The $15 Billion Hepatitis C Market Benzinga
09:56AM  Gilead Sciences: Hep-C Scripts Go Down to the Wire at Barrons.com
12:00AM  The Cost And Value Of Drugs Part Two: Benefits And Effectiveness at Forbes
Dec-11-14 05:47PM  Philadelphia transit system sues Gilead Sciences over $1,000-a-pill drug at Los Angeles Times
05:38PM  How Can Drugmakers Handle New Pricing Pressures? at Investor's Business Daily
12:50PM  Six Reasons Gilead Sciences Will Head Higher in 2015 at Barrons.com
12:06PM  Gilead Sciences Bucks Trend In Biotech Short Interest Benzinga
10:21AM  Will AbbVie Undercut Gilead on Hepatitis C? at Barrons.com
08:01AM  Gilead Is Growing Fast And Its Stock Is Cheap at Barrons.com
12:12AM  Gilead Faces Suit Over Hepatitis Drugs Price at The Wall Street Journal
Dec-10-14 06:50PM  Gilead Sciences sued over hepatitis C drug's $1000-a-pill price tag at San Jose Mercury News
05:59PM  Gilead faces lawsuit over hepatitis C drug pricing AP
04:43PM  Gilead Faces Suit Over Drug's Price at The Wall Street Journal
04:21PM  Newscast: Oil called the tune on Wall St. at MarketWatch
03:55PM  Gilead sued over 'exorbitant' hepatitis C drug prices Reuters
03:37PM  Gilead sued over pricing of hepatitis C drug at CNBC
Dec-09-14 01:45PM  Gilead Sciences: Still Waiting on AbbVie at Barrons.com
Dec-08-14 01:25PM  Stocks Fall To Session Lows: GoPro Gives Up More Ground at Investor's Business Daily
12:37PM  Celgene CEO: Cancer drug pipeline booming CNBC
12:02PM  Stock Market Today: Jazz Hits New High, In Buy Range at Investor's Business Daily
11:29AM  Gilead Sciences: How Much Will You Pay for Its Hepatitis C Drugs? at Barrons.com
10:00AM  Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma Business Wire
09:09AM  Merck-Cubist deal about 'superbugs' CNBC
Dec-05-14 04:25PM  A surprisingly stronger than expected monthly payroll report... Yahoo Finance Blogs
12:18PM  Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences at TheStreet
10:50AM  Gilead Sciences Spikes Higher As Barron's Suggests Looking Beyond Hepatitis-C Benzinga
09:55AM  Cramer's Stop Trading: Gilead CNBC
09:42AM  Gilead Sciences: Time to Look Beyond Hepatitis C? at Barrons.com
Dec-04-14 07:54PM  Can Health Care Sector's Fund Romp Continue? at Investor's Business Daily
Dec-03-14 06:04PM  Most active Nasdaq-traded stocks AP
Dec-02-14 04:45PM  Mylan, Gilead Ink Deal for TAF-based HIV Drugs Zacks
10:30AM  Gilead Sciences: Less Now, More Later at Barrons.com
Dec-01-14 02:35PM  GILEAD SCIENCES INC Files SEC form 8-K, Other Events EDGAR Online
12:49PM  Midday movers: Apple, Tesla Motors, Amazon.com & more at CNBC
12:16PM  Gilead Sciences: 'Current Purgatory' a 'Good Time to Buy' at Barrons.com
10:24AM  Mylan to Manufacture, Distribute Gilead Sciences HIV Drug at The Wall Street Journal
09:23AM  Story Stocks from Briefing.com Briefing.com
Nov-30-14 07:01PM  AbbVie adds children's AIDS drugs to shared patent pool Reuters
Nov-28-14 10:16AM  Gilead Sciences: New Prescriptions for Hepatitis C Drugs Slow at Barrons.com
Nov-26-14 12:29PM  Bristol-Myers Hepatitis C Drug Needs More Data on Combinations at Bloomberg
12:20PM  FDA Seeks More Data on Bristol-Myers Hepatitis C Therapy at The Wall Street Journal
Nov-25-14 01:05PM  More Medicine Goes Off Limits In U.S. Drug-Price Showdown Bloomberg
07:25AM  Nations thrive by uniting professors and entrepreneurs at Financial Times
06:12AM  Why You Shouldn't Bet Against Gilead Sciences (GILD) Stock Zacks
06:00AM  'Mad Money' Lightning Round: I Think Twitter Needs a New CEO at TheStreet
Nov-24-14 04:44PM  Can Partnering To Fight Hepatitis C Pay At Entanta? at Investor's Business Daily
04:44PM  Can Partnering To Fight Hepatitis C Pay At Enanta? at Investor's Business Daily
10:54AM  Hedge funds playing buy-and-hold, and losing at CNBC
Nov-21-14 01:11PM  Good Week for Gilead's Hepatitis-C Treatments, UBS Says at Barrons.com
12:28PM  AbbVie, Celgene, Sanofi Drugs Get EU Endorsements at Investor's Business Daily
Nov-20-14 03:27PM  Gilead to Buy Knight Therapeutics' Priority Review Voucher Zacks
01:48PM  Ooh La La: France Negotiates a Steep Discount for Sovaldi From Gilead at The Wall Street Journal
08:20AM  France pegs Gilead hepatitis C drug at "lowest price in Europe" Reuters
Nov-19-14 04:57PM  Gilead Gains on Harvoni's EU Approval for HCV Treatment Zacks
03:41PM  How Much? Gilead Pays $125M For an FDA Priority Review Voucher at The Wall Street Journal
01:12PM  Gilead Sciences: The Worst Case Scenario? at Barrons.com
10:23AM  Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU Zacks
09:37AM  Screening Pharma Stocks Amid Turnaround YCharts
Nov-18-14 02:39PM  The Buzziest Biotech Stocks on Social Media Yahoo Finance Blogs
02:38PM  Stock Movers: Why 4 Big Drug Stocks Are Rising Today at Investor's Business Daily
11:46AM  Gilead Sciences: Harvoni Gets European Marketing OK at Barrons.com
10:48AM  Gilead Sciences (GILD) Stock Rises After European Commission Market Authorization for Harvoni at TheStreet
10:07AM  European Commission Grants Marketing Authorization for Gileads HarvoniĀ® (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4 Business Wire
Nov-17-14 05:28PM  Halliburton Paying a Premium for Baker Hughes at The Wall Street Journal
04:27PM  GILEAD SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Ob EDGAR Online
03:58PM  Incyte Building Blockbuster Drug One Disease At A Time at Investor's Business Daily
10:03AM  Gilead: What About Its Pipeline? at Barrons.com
Nov-15-14 09:57AM  Julian Robertson's Tiger Management 13F Reveals Huge Alibaba Stake Benzinga
Nov-14-14 06:22PM  Biotech Stocks Hit: Stock Market To See New Leaders? at Investor's Business Daily
05:00PM  Biotech correction coming? 16 trades, 55 seconds CNBC
04:21PM  All in all, another solid week for U.S. equities... Yahoo Finance Blogs
01:04PM  GILEAD SCIENCES INC Financials EDGAR Online Financials
08:48AM  Can Gilead Double From Here? at Forbes
Nov-13-14 08:20PM  Are Health Care Funds Taking PEDs? at Investor's Business Daily
06:58PM  Which Health Care ETF Should You Buy? at Investor's Business Daily
05:45PM  Stock Pops & Drops: KING, BABA, SNDK & GILD CNBC
03:48PM  Can Gilead Recover from 3Q? at Barrons.com
01:37PM  Gilead Sciences In Correction Mode Benzinga
09:15AM  4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic at 24/7 Wall St.
08:31AM  Is A Boston University Professor's Plan For Lower Drug Costs Viable? at Forbes
07:36AM  The Zacks Analyst Blog Highlights: Dendreon, Amgen, Regeneron, AbbVie and Gilead Zacks
Nov-12-14 06:02PM  Your first trade for Thursday at CNBC
05:59PM  Gilead Prices $4 Billion of Senior Unsecured Notes Business Wire
04:00PM  Gilead Reports Promising Data on its HCV Drug Harvoni Zacks
01:35PM  Gilead Sees Large Insider Stock Sale Into Debt Offering at 24/7 Wall St.
12:59PM  FMHR Final Trade: Dunkin, Twitter & more CNBC
07:48AM  Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy Zacks
07:44AM  #PreMarket Primer: Wednesday, November 12: Banks Fined More Than $3 Billion For Role In Forex Manipulation Benzinga
Nov-11-14 11:26AM  Gilead hepatitis C drug highly effective in cirrhosis patients Reuters
09:00AM  AbbVie Hepatitis C Drug Cures 97% in Transplant Patients Study at Bloomberg
08:31AM  Stock Market News for November 11, 2014 Zacks
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLIGAN JOHN FPresident and COODec 08Option Exercise8.01146,8231,175,3181,120,871Dec 10 05:32 PM
MILLIGAN JOHN FPresident and COODec 08Sale106.26146,82315,601,122974,048Dec 10 05:32 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise8.01140,6331,125,7674,263,620Dec 03 07:13 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise40.562,00081,12036,308Dec 03 07:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.2931,000752,947149,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Option Exercise26.995,000134,95020,641Dec 03 03:46 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale100.022,000200,03134,308Dec 03 07:14 PM
MARTIN JOHN CChairman and CEODec 01Sale100.72140,63314,164,8294,122,987Dec 03 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale100.7933,0003,325,922116,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Sale100.195,000500,96915,641Dec 03 03:46 PM
Cogan John FrancisDirectorNov 21Option Exercise14.3425,000358,43867,405Nov 25 04:10 PM
Cogan John FrancisDirectorNov 21Sale101.2325,0002,530,77042,405Nov 25 04:10 PM
MILLIGAN JOHN FPresident and COONov 07Option Exercise8.01146,8951,175,8941,120,943Nov 12 12:48 PM
MILLIGAN JOHN FPresident and COONov 07Sale107.37146,89515,772,736974,048Nov 12 12:48 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000055,832Nov 07 01:20 PM
Carter Paul RutherfordEVP Commercial OpsNov 04Option Exercise0.004,800037,044Nov 05 05:37 PM
Whitley Richard JamesDirectorNov 03Option Exercise26.995,000134,95020,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Option Exercise8.01140,6251,125,7034,570,012Nov 05 02:05 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Option Exercise40.563,000121,68035,244Nov 05 05:37 PM
Washington Robin LEVP, CFONov 03Option Exercise25.1433,192834,58683,024Nov 05 08:06 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Sale112.463,000337,38032,244Nov 05 05:37 PM
Whitley Richard JamesDirectorNov 03Sale112.025,000560,09015,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Sale110.40140,62515,525,1024,429,387Nov 05 02:05 PM
Washington Robin LEVP, CFONov 03Sale110.2633,1923,659,83749,832Nov 05 08:06 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Option Exercise40.562,00081,12034,244Oct 28 01:35 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Sale110.002,000220,00732,244Oct 28 01:35 PM
Cogan John FrancisDirectorOct 21Option Exercise14.3415,000215,06357,405Oct 23 01:54 PM
Cogan John FrancisDirectorOct 21Sale104.0815,0001,561,14942,405Oct 23 01:54 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise8.01146,8951,175,8941,120,943Oct 09 02:10 PM
MILLIGAN JOHN FPresident and COOOct 07Sale104.60146,89515,365,818974,048Oct 09 02:10 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise23.7631,000736,405153,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise8.01140,6251,125,7034,570,012Oct 03 02:57 PM
MARTIN JOHN CChairman and CEOOct 01Sale105.91140,62514,893,8454,429,387Oct 03 02:57 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale105.9833,0003,497,259120,694Oct 03 02:53 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Option Exercise40.562,00081,12034,244Sep 30 01:19 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Sale107.472,000214,94532,244Sep 30 01:19 PM
Cogan John FrancisDirectorSep 22Option Exercise14.345,00071,68847,405Sep 24 01:20 PM
Cogan John FrancisDirectorSep 22Sale106.605,000532,98742,405Sep 24 01:20 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise8.01146,8951,175,8941,120,943Sep 10 04:06 PM
MILLIGAN JOHN FPresident and COOSep 08Sale105.99146,89515,569,664974,048Sep 10 04:06 PM
Whitley Richard JamesDirectorSep 02Option Exercise26.995,000134,95020,641Sep 04 04:31 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Option Exercise23.7631,000736,405155,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Option Exercise8.01140,6251,125,7034,570,012Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Sale108.105,000540,50015,641Sep 04 04:31 PM
MARTIN JOHN CChairman and CEOSep 02Sale108.64140,62515,277,9144,429,387Sep 04 05:09 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Sale108.5833,0003,583,230122,694Sep 04 05:09 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Option Exercise19.0910,000190,85042,244Aug 28 02:35 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Sale106.1610,0001,061,61832,244Aug 28 02:35 PM
Cogan John FrancisDirectorAug 21Option Exercise14.345,00071,68847,405Aug 25 12:21 PM
Cogan John FrancisDirectorAug 21Sale101.095,000505,44042,405Aug 25 12:21 PM
Washington Robin LEVP, CFOAug 14Option Exercise40.5633,5561,361,03183,388Aug 18 01:10 PM
Washington Robin LEVP, CFOAug 14Sale95.5633,5563,206,61149,832Aug 18 01:10 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Option Exercise26.9916,728451,48948,713Aug 12 04:25 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Sale91.5816,7281,531,88131,985Aug 12 04:25 PM
Washington Robin LEVP, CFOAug 01Option Exercise22.3030,600682,49080,432Aug 05 01:35 PM
Whitley Richard JamesDirectorAug 01Option Exercise26.995,000134,95020,641Aug 05 05:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise0.002,500033,205Aug 05 05:31 PM
MARTIN JOHN CChairman and CEOAug 01Option Exercise8.01140,6251,125,7034,570,012Aug 04 06:16 PM
MARTIN JOHN CChairman and CEOAug 01Sale91.53140,62512,871,8134,429,387Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Sale91.005,000455,00015,641Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Sale91.4830,6002,799,34849,832Aug 05 01:35 PM
MOORE NICHOLAS GDirectorJul 28Option Exercise26.6245,0001,197,67545,000Jul 30 12:17 PM
MOORE NICHOLAS GDirectorJul 28Sale90.5645,0004,075,4030Jul 30 12:17 PM
Cogan John FrancisDirectorJul 21Option Exercise14.345,00071,68847,405Jul 23 01:31 PM
Cogan John FrancisDirectorJul 21Sale89.675,000448,34342,405Jul 23 01:31 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Option Exercise26.9916,728451,48947,433Jul 10 01:41 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Sale86.4516,7281,446,07430,705Jul 10 01:41 PM
Whitley Richard JamesDirectorJul 01Option Exercise26.995,000134,95020,641Jul 02 04:24 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise8.01140,6251,125,7034,570,012Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.6131,000731,853159,694Jul 03 03:14 PM
MARTIN JOHN CChairman and CEOJul 01Sale84.84140,62511,929,9614,429,387Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale84.1233,0002,776,076126,694Jul 03 03:14 PM
Whitley Richard JamesDirectorJul 01Sale83.655,000418,25015,641Jul 02 04:24 PM
Washington Robin LEVP, CFOJun 30Sale83.9810,400873,40346,774Jul 02 01:44 PM
Cogan John FrancisDirectorJun 23Option Exercise14.345,00071,68847,405Jun 25 01:51 PM
Cogan John FrancisDirectorJun 23Sale81.825,000409,12342,405Jun 25 01:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Option Exercise16.4090,0001,475,550209,302Jun 18 04:33 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Sale80.9090,0007,280,784119,302Jun 18 04:33 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Option Exercise26.9916,728451,48947,433Jun 11 12:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Sale79.4316,7281,328,64530,705Jun 11 12:59 PM
Washington Robin LEVP, CFOJun 04Sale82.526,426530,27457,174Jun 05 05:46 PM
Whitley Richard JamesDirectorJun 02Option Exercise26.995,000134,95020,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Option Exercise23.6031,000731,600161,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Option Exercise8.01140,6251,125,7034,570,012Jun 04 02:48 PM
Whitley Richard JamesDirectorJun 02Sale80.955,000404,75015,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Sale81.3533,0002,684,514128,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Sale81.32140,62511,435,8364,429,387Jun 04 02:48 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Option Exercise16.4090,0001,475,550209,302May 16 02:52 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Sale80.6590,0007,258,752119,302May 16 02:52 PM
Carter Paul RutherfordEVP Commercial OpsMay 10Option Exercise0.005,000021,290May 13 02:27 PM
MILLIGAN JOHN FPresident and COOMay 08Option Exercise8.01100,000800,5001,038,048May 09 06:58 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Option Exercise23.3340,000933,132170,694May 12 03:38 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Sale80.0040,0003,200,000130,694May 12 03:38 PM
Washington Robin LEVP, CFOMay 06Option Exercise24.913,00074,71552,832May 08 07:13 PM
Washington Robin LEVP, CFOMay 06Sale79.913,000239,73049,832May 08 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise21.5811,000237,325143,694May 05 05:23 PM
Whitley Richard JamesDirectorMay 01Option Exercise26.995,000134,95017,778May 05 05:36 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise8.01140,6251,125,7034,570,012May 05 05:52 PM
Whitley Richard JamesDirectorMay 01Sale78.635,000393,15012,778May 05 05:36 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale79.0813,0001,028,024130,694May 05 05:23 PM